Clinical Trial Update: Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating weekly Taxotere (docetaxel) and irinotecan (CPT-11) for advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Camptosar (irinotecan)
• Taxotere (docetaxel)

Snippet

Sponsor: Sanofi | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED